Macrophages As Key Drivers of Cancer Progression and Metastasis

Overview

Journal Mediators Inflamm

Publisher Wiley

Specialties Biochemistry
Pathology

Date 2017 Feb 18

PMID 28210073

Citations 160

Authors

Sebastian R Nielsen

Michael C Schmid

Affiliations

Soon will be listed here.

Abstract

Macrophages are one of the most abundant immune cells in the tumour microenvironment of solid tumours and their presence correlates with reduced survival in most cancers. Macrophages are present at all stages of tumour progression and stimulate angiogenesis, tumour cell invasion, and intravasation at the primary site. At the metastatic site, macrophages and monocytes prepare for the arrival of disseminated tumour cells and promote their extravasation and survival by inhibiting immune-mediated clearance or by directly engaging with tumour cells to activate prosurvival signalling pathways. In addition, macrophages promote the growth of disseminated tumour cells at the metastatic site by organising the formation of a supportive metastatic niche. The development of agents inhibiting the recruitment or the protumorigenic effector functions of macrophages in both the primary tumour and at the metastatic site is a promising strategy to improve cancer survival in the future.

Citing Articles

Cell fusion as a driver of metastasis: re-evaluating an old hypothesis in the age of cancer heterogeneity.

Lopez-Collazo E, Hurtado-Navarro L Front Immunol. 2025; 16:1524781.

PMID: 39967663 PMC: 11832717. DOI: 10.3389/fimmu.2025.1524781.

Nutritional, Nutraceutical, and Medicinal Potential of Fr.: A Comprehensive Review.

Kumar A, Devi R, Dhalaria R, Tapwal A, Verma R, Rashid S Food Sci Nutr. 2025; 13(1):e4641.

PMID: 39803245 PMC: 11717058. DOI: 10.1002/fsn3.4641.

High systemic inflammation response index (SIRI) level as a prognostic factor for colorectal cancer patients after curative surgery: a single-center retrospective analysis.

Hayama T, Ochiai H, Ozawa T, Miyata T, Asako K, Fukushima Y Sci Rep. 2025; 15(1):1008.

PMID: 39762444 PMC: 11704263. DOI: 10.1038/s41598-024-84991-z.

PNMA1 is a novel immune modulator and therapeutic target in hepatocellular carcinoma linked to bile acid metabolism.

Chu H, Shan Y, Jiang C, Zhong Y, Liu Z, Fang X Sci Rep. 2025; 15(1):738.

PMID: 39754028 PMC: 11698831. DOI: 10.1038/s41598-024-84368-2.

In vitro treatment of triple-negative breast cancer cells with an extract from the Coriolus versicolor mushroom changes macrophage properties related to tumourigenesis.

Jedrzejewski T, Sobocinska J, Maciejewski B, Spisz P, Walczak-Skierska J, Pomastowski P Immunol Res. 2024; 73(1):14.

PMID: 39680299 DOI: 10.1007/s12026-024-09574-6.

References

McAllister S, Weinberg R . The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis. Nat Cell Biol. 2014; 16(8):717-27. PMC: 6220424. DOI: 10.1038/ncb3015. View

Gil-Bernabe A, Ferjancic S, Tlalka M, Zhao L, Allen P, Im J . Recruitment of monocytes/macrophages by tissue factor-mediated coagulation is essential for metastatic cell survival and premetastatic niche establishment in mice. Blood. 2012; 119(13):3164-75. DOI: 10.1182/blood-2011-08-376426. View

Biswas S, Mantovani A . Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010; 11(10):889-96. DOI: 10.1038/ni.1937. View

Gocheva V, Wang H, Gadea B, Shree T, Hunter K, Garfall A . IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. Genes Dev. 2010; 24(3):241-55. PMC: 2811826. DOI: 10.1101/gad.1874010. View

Grivennikov S, Karin E, Terzic J, Mucida D, Yu G, Vallabhapurapu S . IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell. 2009; 15(2):103-13. PMC: 2667107. DOI: 10.1016/j.ccr.2009.01.001. View

Yona S, Kim K, Wolf Y, Mildner A, Varol D, Breker M . Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. Immunity. 2013; 38(1):79-91. PMC: 3908543. DOI: 10.1016/j.immuni.2012.12.001. View

Caro G, Cortese N, Castino G, Grizzi F, Gavazzi F, Ridolfi C . Dual prognostic significance of tumour-associated macrophages in human pancreatic adenocarcinoma treated or untreated with chemotherapy. Gut. 2015; 65(10):1710-20. DOI: 10.1136/gutjnl-2015-309193. View

Ruffell B, Coussens L . Macrophages and therapeutic resistance in cancer. Cancer Cell. 2015; 27(4):462-72. PMC: 4400235. DOI: 10.1016/j.ccell.2015.02.015. View

Casazza A, Laoui D, Wenes M, Rizzolio S, Bassani N, Mambretti M . Impeding macrophage entry into hypoxic tumor areas by Sema3A/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity. Cancer Cell. 2013; 24(6):695-709. DOI: 10.1016/j.ccr.2013.11.007. View

10.

Lesina M, Kurkowski M, Ludes K, Rose-John S, Treiber M, Kloppel G . Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell. 2011; 19(4):456-69. DOI: 10.1016/j.ccr.2011.03.009. View

11.

Clark C, Hingorani S, Mick R, Combs C, Tuveson D, Vonderheide R . Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res. 2007; 67(19):9518-27. DOI: 10.1158/0008-5472.CAN-07-0175. View

12.

Rolny C, Mazzone M, Tugues S, Laoui D, Johansson I, Coulon C . HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell. 2011; 19(1):31-44. DOI: 10.1016/j.ccr.2010.11.009. View

13.

Lee S, Jilani S, Nikolova G, Carpizo D, Iruela-Arispe M . Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol. 2005; 169(4):681-91. PMC: 2171712. DOI: 10.1083/jcb.200409115. View

14.

Schmid M, Avraamides C, Dippold H, Franco I, Foubert P, Ellies L . Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kγ, a single convergent point promoting tumor inflammation and progression. Cancer Cell. 2011; 19(6):715-27. PMC: 3144144. DOI: 10.1016/j.ccr.2011.04.016. View

15.

Chen J, Lin Y, Yao P, Yuan A, Chen H, Shun C . Tumor-associated macrophages: the double-edged sword in cancer progression. J Clin Oncol. 2004; 23(5):953-64. DOI: 10.1200/JCO.2005.12.172. View

16.

Biswas S, Allavena P, Mantovani A . Tumor-associated macrophages: functional diversity, clinical significance, and open questions. Semin Immunopathol. 2013; 35(5):585-600. DOI: 10.1007/s00281-013-0367-7. View

17.

Wyckoff J, Wang Y, Lin E, Li J, Goswami S, Stanley E . Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res. 2007; 67(6):2649-56. DOI: 10.1158/0008-5472.CAN-06-1823. View

18.

Peinado H, Aleckovic M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno G . Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med. 2012; 18(6):883-91. PMC: 3645291. DOI: 10.1038/nm.2753. View

19.

Grivennikov S, Greten F, Karin M . Immunity, inflammation, and cancer. Cell. 2010; 140(6):883-99. PMC: 2866629. DOI: 10.1016/j.cell.2010.01.025. View

20.

Auffray C, Fogg D, Garfa M, Elain G, Join-Lambert O, Kayal S . Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior. Science. 2007; 317(5838):666-70. DOI: 10.1126/science.1142883. View